| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies, Inc. | Director | Stock Option (Right to Buy) | 10.5K | Jun 17, 2025 | Direct | ||
| Aligos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 5.86K | Jun 25, 2025 | Direct | ||
| DICE Therapeutics, Inc. | Director | Common Stock | 0 | $46.50 | Aug 9, 2023 | By Trust | |
| DICE Therapeutics, Inc. | Director | Common Stock | 0 | $46.50 | Aug 9, 2023 | Direct | |
| DICE Therapeutics, Inc. | Director | Stock Option (right to buy) | 0 | Aug 9, 2023 | Direct |